HCV Treatment at ILC 2022: Selected Highlights

The International Liver Congress (ILC 2022), convened by the European Association for the Study of the Liver (EASL), was held in London, UK on 22-26 June 2022.

Here are selected highlights from ILC 2022 in relation to the HCV treatment:

• Changing HCV Patient Profiles: Insights from a Large Multinational Real-World Sofosbuvir/Velpatasvir (SOF/VEL) Dataset - in Order to Achieve HCV Elimination With Focused Treatment Approaches

• Establishing a Protocol for Management and DAA Treatment of HCV During Pregnancy:
  Adherence to a Co-Located Care Protocol

• Real-Life Effectiveness and Safety of Sofosbuvir/Velpatasvir in Difficult to Treat Hepatitis C Patients

• Long-Term Follow-Up of HCV Resistance-Associated Substitutions After DAA Treatment Failure

• Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner-City Residents: Extending the Results of Clinical Trial

• Sofosbuvir Plus Velpatasvir for 8 Weeks in Patients with Acute Hepatitis C: Multicenter, Single Arm, Phase 2 Study The HepNet Acute HCV V Study

• Association of Sustained Virologic Response With Measures of Direct-Acting Antiviral Adherence in Patients With Hepatitis C: Data from the ASCEND and ANCHOR Investigations

• Efficacy and Safety of Direct-Acting Antivirals in Children and Adolescents with Chronic Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis

• Treating HCV in Dual Diagnosis Acute Psychiatric Inpatients With Substance Use Disorder

• Effectiveness and Safety of 8-Week Glecaprevir/Pibrentasvir in HCV Treatment Naïve Patients With Compensated Cirrhosis: Real-World Experience from Taiwan HCV Registry

• Use of Glecaprevir/Pibrentasvir (G/P) for the Treatment of HCV Infection Among Fentanyl Users: An Interim Analysis of the GRAND PLAN Study - High Cure Rates

• Reported Safety of HCV Direct-Acting Antivirals With Opioids: 2017 to 2021

• Eight Weeks of Glecaprevir/Pibrentasvir is Well Tolerated and Yields High Sustained Virological Response in HCV-Infected Treatment-Naïve Patients With Compensated Cirrhosis: Final Results From the CREST Study

• Healthcare Resource Utilization in Treatment-Naïve Patients With Compensated Cirrhosis Receiving 8-Weeks’ Glecaprevir/Pibrentasvir Stratified by Drug Use and Socioeconomic Status: A Retrospective Chart Review

• Use of Comedication in Patients with Hepatitis C and Addiction or Drug Abuse Treated with Direct-Acting Antivirals: Implication in Drug-Drug Interactions

• Polypharmacy and Prevalence of Multiple Drug-Drug Interactions in Hepatitis C Patients Treated with Pangenotypic Direct-Acting Antivirals: An Analysis from Three European Countries

• Early Post Liver Transplant Rescue Treatment With Sofosbuvir/Velpatasvir/voxilaprevir in Patients Experienced to NS5A-Inhibitors

• Infrequent Hepatitis C Genotypes/Subtypes in Patients Treated with DAA-Based Regimens: Successes and Failures

• Clinical Impact of Drug Interaction in the Use of Antipsychotics by HCV Patients Treated with Pangenotypic Direct-Acting Antivirals

• Don’t Delay Rescue 2nd Line HCV Therapy

• Full-Length Genome Characterization of Inherently Resistant African HCV Genotype 1, Subtype 1l in Patients Failing DAA-Based Therapy

• Effectiveness of Voxilaprevir/Velpatasvir/Sofosbuvir in Hepatitis C Patients Previously Treated with Direct-Acting Antiviral Agents (DAA)

• Voxilaprevir/Velpatasvir/Sofosbuvir Efficacy in hepatitis C Patients Previously Treated With Direct-Acting Antiviral Agents (DAA)

• Glecaprevir/Pibrentasvir & Sofosbuvir for 16 Weeks Without Ribavirin is Safe and Highly Effective Retreatment for Patients Who Have Failed an NS5A Inhibitor Containing Antiviral Regimen

• All-Cause Mortality 3 to 15 Times Higher After HCV SVR Than in General Population

• DAAs Cut Cardio Event Rate in HCV+ But Boost Arrhythmia Risk

• Risk of Dangerous Interactions When Giving DAAs With Other Meds

• GLE/PIB + SOF Effective After Failure of Prior DAAs, Including GLE/PIB

• Multicenter Prospective Study for the Use of Shortened Pre-Emptive Therapy With Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in Hepatitis C (HCV) Seronegative Non-Liver Solid Organ Transplant Recipients of HCV Viremic Grafts

• HCV Cure in People With Psychiatric Disorders is Associated With a Global Reduction in Hospitalizations

• Change in Fibrosis and Clinical Progression Three Years After Sustained Virological Response Induced by Direct Antiviral Agents in HIV/HCV Subjects

• Reverse Inflammaging: Biological age in HCV After Cure

• Evaluation of the Clinical and Economic Value of Sofosbuvir/Velpatasvir (SOF/VEL) in Patients with Chronic Hepatitis C in Spain During the Last 5 Years

• Distinct Hepatocellular Carcinoma Risks in Treated Chronic Hepatitis C Patients With Different Definitions of Advanced Chronic Liver Disease

• Hepatocellular Carcinoma Risks of Liver Fibrosis Changes After Viral Eradication in Chronic Hepatitis C Patients

• Improved Recurrence-Free Survival Rates in Patients With HCV-Related Hepatocellular Carcinoma and Sustained Virological Response to Direct-Acting Antivirals

Source: NATAP